Company: IMNN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001493152-25-011598
Chunk: 3

Company: Imunon, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part II, Item 1A
Chunk 3
---
 capital requirements, including to continue our research and development activities and advance our drug candidates
through various development stages, including the Phase 3 registrational trial of IMNN-001 in advanced ovarian cancer. We are unable
to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive
cash inflows from the commercialization and sale of a product. Our inability to complete any of our research and development activities,
preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could
significantly increase our capital requirements and could adversely impact our liquidity. While our estimated future capital requirements
are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research,
development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization
activities, we will need significant additional capital to develop our drug candidates through development and clinical trials, obtain
regulatory approvals and manufacture and commercialize approved products, if any. We do not know whether we will be able to access additional
capital when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms
reasonably acceptable to us, would jeopardize the future success of our business.

Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item
3. Defaults Upon Senior Securities.

None.

Item
4. Mine Safety Disclosures.

Not
applicable.

Item
5. Other Information.

During
the quarter ended June 30, 2025, no directors or executive officers entered into, modified or terminated, contracts, instructions or
written plans for the sale or purchase of the Company’s securities that were intended to satisfy the affirmative defense conditions
of Rule 10b5-1.

32

Item
6. Exhibits. 

    3.1
    Certificate
                                            of Amendment to the Restated Certificate of Incorporation effective and filed on July 11,
                                            2025, incorporated therein by reference to Exhibit 3.1 to the Current Report on Form 8-K
                                            of the Company filed on July 11, 2025

    3.2
    Certificate
                                            of Amendment to the Restated Certificate of Incorporation, as amended, effective and filed
                                            on July 21, 2025, incorporated therein by reference to Exhibit